Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Malaise
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site swelling; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomitin; Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement; Mild injection site redness; Mild fever (100.4 to 101.2 °F); Moderate fatigue with some interference with activity; Moderate muscle pain with some interference with activity; Joint pain with some interference with activity; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE SWELLING (Moderate injection site swelling), VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomitin) and VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE SWELLING (Moderate injection site swelling), VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomitin), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement), VACCINATION SITE ERYTHEMA (Mild injection site redness), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain with some interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE SWELLING (Moderate injection site swelling), VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomitin), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement), VACCINATION SITE ERYTHEMA (Mild injection site redness), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain with some interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: 100.4 to 101.2 °F.         Concomitant medications were not reported.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case